Halozyme Acquires Elektrofi to Enhance Drug Delivery

The latest update is out from Halozyme ( (HALO) ).

On October 1, 2025, Halozyme announced its acquisition of Elektrofi, a company specializing in ultra-high concentration microparticle technology for biologics, known as Hypercon. This strategic move, approved by both companies’ boards, involves an upfront payment of $750 million and potential milestone payments. The acquisition aims to expand Halozyme’s drug delivery offerings and support long-term revenue growth through Elektrofi’s scalable licensing model. The Hypercon technology allows for higher protein concentrations, facilitating more convenient at-home and healthcare provider office delivery. This acquisition is expected to enhance Halozyme’s industry positioning and provide significant growth opportunities, with royalty revenues anticipated to begin by 2030.

The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Spark’s Take on HALO Stock

According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.

Halozyme’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The technical analysis indicates strong momentum, although caution is advised due to overbought signals. The valuation is reasonable, supporting the overall positive outlook.

To see Spark’s full report on HALO stock, click here.

More about Halozyme

Halozyme Therapeutics, Inc. is a biopharmaceutical company known for its innovative drug delivery technologies, focusing on enhancing the administration of biologics. The company is recognized for its contributions to the biopharma industry, particularly in developing subcutaneous drug delivery systems.

Average Trading Volume: 1,873,658

Technical Sentiment Signal: Buy

Current Market Cap: $8.57B

See more insights into HALO stock on TipRanks’ Stock Analysis page.